

Arkansas Medicaid Direction for the 340B Pilot Model for 2026

Covered entities should continue to follow the Arkansas Medicaid posted 340B Policy.

Covered entities have 3 options for ensuring accurate actual acquisition cost (AAC) billing in the rebate pilot:

- Assume 340B pricing (AAC) when submitting claims to Medicaid, reverse and rebill if rebate claim is denied.
- Hold the Medicaid claim until 340B rebate is authorized and paid; within 10 days.
- Covered entities could carve-out the rebate pilot drugs from 340B and instead:
 - Bill pharmacies using standard pricing, or
 - Bill physician administered drugs (PAD) using the fee schedule.

To enable Medicaid rebate collection, use the following methods to indicate non-340B:

- Pharmacy: Use basis of cost **07** or **13**
- Medical: Apply PAD modifiers (**U7**, or **U7 and UA**)

Current list of participating manufacturers and drugs:

Manufacturer	Drug	Effective Date
Bristol Myers Squibb	ELIQUIS	January 1, 2026
Immunex Corporation	ENBREL	January 1, 2026
Astra Zeneca AB	FARXIGA	January 1, 2026
Pharmacyclics	IMBRUVICA	January 1, 2026
Merck Sharp Dohme	JANUVIA	January 1, 2026
Boehringer Ingelheim	JARDIANCE	January 1, 2026
Novo Nordisk Inc.	NOVOLOG; NOVOLOG FLEXPEN; NOVOLOG PENFILL; FIASP; FIASP FLEXTOUCH; FIASP PENFILL	January 1, 2026
Janssen Biotech, Inc.	STELARA	January 1, 2026
Janssen Pharmaceuticals, Inc.	XARELTO	January 1, 2026
Novartis Pharmaceuticals Corporation	ENTRESTO	April 1, 2026